Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Trial Details

NCT ID
NCT05826535
Phase
PHASE1 / PHASE2
Sponsor
Lyell Immunopharma, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Rondecabtagene autoleucel (ronde-cel)
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Irvine, California, United States|33.66946,-117.82311
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Diego, California, United States|32.71571,-117.16472
  • Denver, Colorado, United States|39.73915,-104.9847

Key Eligibility Criteria

  • Age 18 years or older
  • Willing and able to provide written informed consent
  • Histologically confirmed LBCL, including the following types defined by the World Health Organization (WHO 2022) or International Consensus Classif…
  • Received at least two prior lines of therapy for Cohorts 1, 2, and 4 and one prior line of therapy for Cohort 3

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →